

July 3, 2019

Listing Department
BSE LIMITED
P J Towers, Dalal Street, Fort,
Mumbai-400 001

Code: 532 321

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai-400 051

Code: CADILAHC

Re.: Press Release

Dear Sir / Madam,


Please find enclosed a copy of press release dated July 3, 2019 titled "Zydus receives final approval from the USFDA for Misoprostol Tablets".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**


DHAVAL N. SONI
COMPANY SECRETARY



Encl.: As above

Zy+us receives final approval from the USFDA for Misoprostol Tablets

Ahmedabad, 3 July, 2019

Zy+us Cadila has received the final approval from the USFDA to market Misoprostol Tablets (US RLD – Cytotec®), 100 mcg and 200 mcg. Misoprostol is used to prevent stomach ulcers in patients taking pain medications especially if the patient is at risk for developing ulcers or has a past history of ulcers. Misoprostol helps to decrease risk of serious ulcer complications such as bleeding. The drug will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

The group now has 268 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04.

About Zy+us Cadila

Zy+us Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zy+us aspires to be a research-based pharmaceutical company by 2020.
